Chief Development Officer
Appili Therapeutics
Disclosure(s): No financial relationships to disclose
Gary S. Nabors, Ph.D. is the Chief Development Officer at Appili Therapeutics, Inc. Dr. Nabors is an accomplished biopharmaceutical executive with 30 years industry experience, and a track record for achieving results at small, medium, and large biopharma companies, with an emphasis on vaccines and antibody products for infectious disease indications. He has broad experience in biopharmaceutical product development from pre-clinical stages through Phase 3 for pediatric, adult, travelers’ and biodefense markets. Dr. Nabors received a BA in Biology from Wake Forest University, a Ph.D. in Immunology and Infectious Diseases from The University of Georgia and conducted postdoctoral research at The University of Pennsylvania. He then joined Sanofi Pasteur and served as the head of the Immunology department. Dr. Nabors next joined Emergent BioSolutions and served as SVP of R&D. After serving as a Deputy Director at the National Biological Analysis and Countermeasures Center, Dr. Nabors served as President of DynPort Vaccine Company, and later served as Chief Development Officer at Integrated Biotherapeutics prior to joining Appili Therapeutics. He has worked on vaccines and therapeutics against many pathogens including anthrax, botulism, plague, Helicobacter, influenza, pneumococcus, meningococcus, shigella, Leishmania, Lyme disease, tularemia, Staphylococcus aureus and Ebola virus.